WallStSmart

biote Corp (BTMD)vsJohnson & Johnson (JNJ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 51945% more annual revenue ($97.93B vs $188.16M). JNJ leads profitability with a 21.5% profit margin vs 8.3%. BTMD trades at a lower P/E of 5.3x. JNJ earns a higher WallStSmart Score of 57/100 (C).

BTMD

Hold

35

out of 100

Grade: F

Growth: 3.3Profit: 6.5Value: 8.3Quality: 7.0
Piotroski: 5/9Altman Z: 2.74

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BTMDUndervalued (+46.5%)

Margin of Safety

+46.5%

Fair Value

$3.96

Current Price

$1.54

$2.42 discount

UndervaluedFair: $3.96Overvalued
JNJSignificantly Overvalued (-87.3%)

Margin of Safety

-87.3%

Fair Value

$139.75

Current Price

$259.74

$119.99 premium

UndervaluedFair: $139.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BTMD2 strengths · Avg: 10.0/10
P/E RatioValuation
5.3x10/10

Attractively priced relative to earnings

Debt/EquityHealth
-1.9310/10

Conservative balance sheet, low leverage

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$614.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
29.2%8/10

Strong operational efficiency at 29.2%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

Areas to Watch

BTMD4 concerns · Avg: 2.5/10
Market CapQuality
$80.35M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

EPS GrowthGrowth
-83.8%2/10

Earnings declined 83.8%

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
29.5x4/10

Moderate valuation

PEG RatioValuation
4.232/10

Expensive relative to growth rate

EPS GrowthGrowth
-0.9%2/10

Earnings declined 0.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : BTMD

The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.

Bear Case : BTMD

The primary concerns for BTMD are Market Cap, Return on Equity, Revenue Growth.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BTMD profiles as a value stock while JNJ is a mature play — different risk/reward profiles.

BTMD carries more volatility with a beta of 1.65 — expect wider price swings.

JNJ is growing revenue faster at 6.6% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (57/100 vs 35/100), backed by strong 21.5% margins. BTMD offers better value entry with a 46.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

biote Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

biote corp. The company is headquartered in Irvine, Texas.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?